LNTH-2501 (Gallium-68 edotreotide)

Updated August 8, 2026·next FDA decision on the calendar

LNTH-2501 (Gallium-68 edotreotide) is a Lantheus Holdings Inc. program in Neuroendocrine tumors (NETs) in adult and pediatric patients. 1 FDA decision on record below. Every date links its source.

LNTH catalyst hub

Catalyst history

PDUFA · Jun 29, 2026 CRLLNTH

Facts and dates only; not investment advice. Verify against primary FDA, SEC and company filings. pdufa.bio is not affiliated with the FDA.

About · Corrections · Methodology

Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.

Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.

© 2026 pdufa.bio. All rights reserved.